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Open Forum Infectious Diseases
REVIEW ARTICLE

Interventions to Increase Completion of Hepatitis B
Vaccination in People who Inject Drugs: A Systematic
Review and Meta-analysis
Stacy Tressler and Ruchi Bhandari
Department of Epidemiology, West Virginia University, Morgantown, West Virginia, USA

Globally, ~90% of the world’s population lives in countries with
a high or intermediate prevalence of hepatitis B [1]. Worldwide,
~240 million people are chronically infected with hepatitis B
virus (HBV), and in the Unites States, an estimated 2.2 million
people are chronic carriers of the virus [2, 3]. It is estimated that
chronic hepatitis B (CHB) infection is responsible for 50% of
all cases of hepatocellular carcinoma, and 25% of people with
CHB will die prematurely from complications of the disease [1].
Major risk factors for HBV infection in the United States include sexual exposure and injection drug use (IDU) [4]. Since
2009, opioid misuse and IDU in the United States have resulted
in an increase in acute cases of hepatitis B [2]. In 2015, 30.3%
of newly HBV-infected people reported IDU as a risk factor
[4]. Adults with compromised immune systems are more likely
to develop chronic infection (20%) compared with those with
a healthy immune system (5%) [1]. People who inject drugs
(PWID) have a higher risk of developing chronic infection due
to altered immune function and co-infections with hepatitis C
virus (HCV) and HIV [5].

The rise in opioid misuse and IDU has highlighted the need
to provide education and harm reduction services to PWID, including HBV vaccination [2, 6]. Survey data from 2013 indicate
that only one-third of adults have completed the 3-dose HBV
vaccination series, and this number is estimated to be even lower
in PWID [2]. PWID can be a difficult population to reach, and
completion of the standard 3-dose series at 0, 1, and 6 months
in this population can be challenging. For this reason, different
strategies have been used to increase vaccination rates, including
accelerated vaccine schedules, financial incentives, case management, peer coaching, and motivational interviewing [7–17]. In
2014, The World Health Organization (WHO) published guidance on preventing HBV and HCV in PWID. Using a systematic
review approach, the authors graded the quality of evidence for
using an accelerated vaccine schedule, financial incentives, and
peer-based strategies to improve health outcomes for people with
substance use disorders [3]. Although the quality of the evidence
supporting these strategies was low, the WHO recommends their
use to prevent the transmission of HBV and HCV in PWID [3].
Objective
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The primary objective of this study was to conduct a systematic
review and meta-analysis of randomized controlled trials and
randomized studies to determine the overall effect of strategies
to increase HBV vaccination in PWID.
METHODS
Study Eligibility

The eligibility criteria for inclusion in this systematic review
with meta-analysis were established a priori. Each study was
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Increases in opioid misuse and injection drug use have resulted in a rise in acute cases of hepatitis B. We conducted a systematic review
and meta-analysis of randomized studies to determine the effect (pooled odds ratio) of interventions to increase hepatitis B vaccination
completion in people who inject drugs (PWID). Odds ratios from the included studies were combined to create a pooled odds ratio (OR)
using the Inverse Heterogeneity Model. Eleven studies met the eligibility criterion of having a randomized intervention to increase hepatitis
B virus vaccination completion among PWID. The odds of vaccine completion in the intervention group were greater than in the control/
comparison group (pooled OR, 2.53; 95% confidence interval [CI], 1.07–5.99). Subgroup analysis indicated that financial incentives were
most effective (OR, 7.01; 95% CI, 2.88–17.06), followed by accelerated vaccine schedules (OR, 1.90; 95% CI, 1.14–3.14). Interventions using
financial incentives and accelerated vaccine schedules are moderately effective at increasing hepatitis B vaccination completion in PWID.
Keywords. hepatitis B; meta-analysis; people who inject drugs; vaccination.

required to meet the following eligibility criteria: (1) randomized controlled trial or randomized study with at least 1
intervention group and 1 control/comparison group, (2) intervention aimed at increasing adherence to completion of the
HBV vaccine series as either a primary or secondary outcome,
(3) outcome data available on completion of the 3-dose HBV
vaccination series, and (4) a study sample that included PWID
(representing either all or a percentage of the overall study
sample). The gray literature was not searched, and only studies
published in English were included.

An electronic search of PubMed, Web of Science, and Cochrane
Library was performed on February 20, 2018. Search terms included “inject*,” “drug use*,” “hepatitis B vacc*,” and “hepatitis
B vaccine*.” MESH terms included “hepatitis B vaccines” and
“substance abuse, intravenous.” There were no time restrictions
placed on the search, and each database was searched from its
inception through February 20, 2018. Hand-searching of references was performed when reviewing relevant studies to identify randomized controlled trials (RCTs) not found during the
electronic search. An additional search of the 3 databases was
performed on June 19, 2019, to search for studies meeting the
inclusion criteria that were published between February 20,
2018, and June 19, 2019. No additional studies were identified.

Records identified through database
searching
(n = 565)

Studies obtained from the search results were imported into
EndNote (VXE; Thomas Reuters, New York, NY, USA).
Duplicates were identified and removed. Titles and abstracts
were reviewed to identify studies meeting the inclusion criteria.
A flowchart detailing the exclusion process and the reasons for
exclusion can be found in Figure 1. For studies using the same
sample, the study with the data most relevant to the review topic
was selected.
Data Extraction

Microsoft Excel (version 2010; Richmond, WA, USA) was used
to develop a codebook for data extraction before article selection. Each study was coded on 51 items, including the following
major categories of variables: (1) study characteristics, (2) intervention characteristics, (3) participant characteristics, and
(4) outcome characteristics. For studies with >1 intervention
group, outcome data for the most intensive intervention were
selected. If a true control group did not exist, the comparison
group selected by the study authors was used. Data were included in the meta-analysis even if studies reported outcome
data for a PWID subpopulation.
Risk of Bias Assessment

Risk of bias was assessed for each included study using the
Cochrane Risk of Bias tool [18]. Study bias was assessed as high,

Additional records identified through
other sources
(n = 3)

Records after duplicates removed
(n = 496)

Records screened
(n = 496)

Full-text articles assessed for eligibility
(n = 60)

Studies included in quantitative synthesis
(meta-analysis)
(n = 11)
Figure 1.

Flowchart of study selection.
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Records excluded
(n = 436)
• Not related to the review topic (n = 226)
• Wrong study design (n = 172)
• Wrong population (n = 23)
• Wrong outcome (n = 9)
• Systematic review or meta-analysis (n = 6)

Full-text articles excluded
(n = 49)
• Wrong study design (n =34)
• Wrong population (n = 1)
• Wrong outcome (n = 7)
• Same sample as another study (n = 6)
• Unable to retrieve full study (n = 1)
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Data Sources

Study Selection

low, or unclear on the following measures: (1) random sequence
generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome data, (5) incomplete outcome data, (6) selective reporting, and (7) other major
sources of bias.
Statistical Analysis

RESULTS
Study Characteristics

A flowchart depicting the search strategy and study selection
process can be found in Figure 1. A total of 565 studies were
identified through electronic database searches. An additional
3 studies were identified through hand-searching references
during review of full articles, for a total of 568 studies. Using
both electronic and manual searching methods, 72 duplicates were identified and removed. A total of 496 studies were
screened for eligibility, resulting in the removal of 485 studies.
Eleven studies, representing 4027 participants, met the selection criteria and were included in the meta-analysis. All of the
studies included adherence to the 3-dose HBV vaccine series as
their primary outcome. Countries where the studies were conducted included the United States (n = 7) Iran (n = 1), Denmark
(n = 1), Australia (n = 1), and the United Kingdom (n = 1).
Study settings included prison (n = 2), syringe exchange program (n = 2), methadone maintenance program (n = 2), drug
treatment program (n = 2), community (n = 1), streets in an
urban area (n = 1), and a combination of shelters, drug treatment facility, and streets (n = 1). An overview of study characteristics can be found in Table 1.
Participant Characteristics

The mean age of participants ranged from 34 to 46.3 years.
Studies had a greater proportion of males compared with

Intervention Characteristics

Interventions were classified into 3 main categories: (1) HBV
vaccine schedule (n = 4), (2) monetary/financial incentives
(n = 3), and (3) case management/enhanced services (n = 4).
Four studies focused on schedule-based interventions using
a variety of accelerated vaccine schedules for the intervention
group and all controls/comparisons assigned to the standard
schedule of 0, 1, and 6 months. Three studies used monetary
or financial intervention, and incentives included cash and
vouchers in both fixed and escalating amounts. Details of the
amounts used in each study can be found in Table 1. The case
management/enhanced services interventions included motivational interviewing, case management, coaching, and hepatitis
care coordination. Study characteristics can be found in Table 1.
Risk of Bias Assessment

The Cochrane Risk of Bias assessment tool was used to rank
the studies as having high, low, or unclear risk of bias on 7 domains (Supplementary Figure 1). Due to the nature of the interventions, almost all studies were ranked as having a high risk
of bias, based on 3 criteria: allocation concealment, blinding
of participants and personnel, and blinding of outcome assessment. For all studies, the risk of bias for selective outcome reporting was low. The risk of bias varied among studies for the
other 3 criteria, namely random sequence generation, incomplete outcome data, and other issues.
Data Synthesis

Results of the OR for vaccine completion in the intervention group compared with the control/comparison group can
be found in Figure 2. An overall pooled OR of 2.53 (95% CI,
1.07–5.99) indicated a statistically significant (P = .04) increase
in the odds of completing the 3-dose vaccine in the intervention groups compared with the control/comparison group.
Study heterogeneity was statistically significant (P < .0001),
and inconsistency was categorized as high (I2 = 89%). An influence analysis with each study excluded once revealed that
results did not remain statistically significant when 4 of the 11
studies were individually removed from the model once. The
results of the influence analysis can be found in Supplementary
Table 1. A cumulative meta-analysis of the studies by year
(Supplementary Figure 2) showed that the ORs in the studies
HepB Vaccination Completion in PWID • ofid • 3
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All analyses were completed in Meta XL using the Inverse
Heterogeneity Model (IVhet). Data on studies reporting adjusted and crude odds ratios (ORs) of completion of the 3-dose
HBV vaccination series in the intervention group compared
with the control/comparison group were entered into Meta XL.
Adjusted and crude odds ratios were pooled to create an overall
effect size. Pooled ORs with 95% confidence intervals (CIs)
were calculated using the IVhet in Meta XL. Heterogeneity and
inconsistency were assessed using the Q statistic (based on the
chi-square test statistic) and I2. For the Q statistic, a P value <.10
was indicative of statistically significant heterogeneity between
studies. I2 scores of 25% (low), 50% (moderate), and 75% (high)
were used to determine the amount of inconsistency between
studies. Small-study effects were assessed using a funnel plot.
Cumulative, influence, and subgroup analyses were conducted.
Subgroup analyses included intervention type (accelerated, financial, and case management or enhanced services) and reported OR (adjusted vs crude).

females, with a range of 55% to 100% males. The studies varied
on the percentage of participants who reported IDU and ranged
from 8.9% to 100%. Five studies included only participants who
reported IDU, and the other 6 studies included participants
who reported IDU and other alcohol/drug use. Ten studies
based IDU on self-report, and each study differed on whether
the IDU was classified as current, recent, ever/lifetime, or future risk. The only common variables reported for all 11 studies
were percent IDU and percent males. Participant characteristics
can be found in Table 1.

United States

United States

United States

United States

Australia

United Kingdom Drug treatment centers Cluster RCT

Nyamathi et al.
2009 [13]

Nyamathi et al.
2015 [14]

Nyamathi et al.
2010 [15]

Seal et al.
2003 [7]

Topp et al.
2013 [16]

Weaver et al.
2014 [17]

RCT

RCT

RCT

210

139

96

148

345

865

300

1260

34

461

169

Randomized &
Vaccine
Eligible, No.

d

Calculated from the mean age of the intervention and control groups.

Not reported.

c

Monetary (voucher)

Monetary (voucher)

Monetary

Case management/
enhanced services

Case management/
enhanced services

Case management/
enhanced services

Case management/
enhanced services

Vaccine schedule

Vaccine schedule

Vaccine schedule

Vaccine schedule

Type of Intervention

Fixed amount: £10 with each
dose; escalating amounts:
£5 1st dose, £10 2nd dose,
£15 3rd dose

AU $20 at first visit,
AU $30 at dose 2, AU $30
at dose 3, and AU $30 cash
at study follow-up visit

$20 monthly for 6 months

1-on-1 MI

Intensive peer coaching and
nurse case management

Nurse case management, $5
incentive per dose, and
tracking

Enhanced care coordination
2-session counseling with
MI, on-site testing &
vaccination, enhanced
case management

0, 1, 2 mo

0, 1, 3 wk

0, 1, 2 mo

0, 1, 4, 8 wk

Intervention

Did not report demographic information for the randomized study. Only reported demographic information for the nonrandomized follow-up study that took place in Estonia.

For the total study (n = 1964), retrieved from Heimer et al. paper [22].

b

a

Abbreviations: IDU, injection drug use; MI, motivational interviewing; RCT, randomized controlled trial.

Inner-city health service RCT
clinic in a syringe exchange program

Community—recruited RCT
from the streets

Methadone maintenance treatment
programs (urban)

Residential drug treatment facility (urban)

Homeless shelters,
Randomized
residential drug treatment programs, and
outdoor areas

Methadone maintenance treatment
program

United States

Masson et al.
2013 [12]

RCT

Community

Randomized

Randomized

United States

Syringe exchange program

RCT

Hwang et al.
2010 [11]

United States

Bowman et al.
2014 [10]

Prison and corrections
facility

Prison

Iran

Asli et al.
2011 [9]

Setting

Christensen et al. Denmark
2004 [8]

Country

Study
Design

Study and Participant Characteristics of the 11 Studies Included in the Meta-analysis

Study

Table 1.

73a
b

77
68

76.7

100

40.4a
b

c

44.85d

42.3

42
46.3

43
33.1

36.2

Standard vaccine schedule
Standard vaccine schedule
Standard vaccine schedule
2-session counseling,
on-site testing, off-site
vaccination and
evaluation
Standard hepatitis training
with $5 incentive per
dose
Usual care
Nurse-led hepatitis health
promotion
Maintain weekly contact
with an outreach worker
Standard care plus AU $20
voucher at first visit and
AU $30 cash at study
follow-up visit
Treatment as usual with no
incentive

80

77

72

55

100

100 (previous,
current, or
at-risk for
future)

100 (previous
6 mo)

100 (current)

34.4 (recent)

32.5 (lifetime)

16.7 (lifetime)
6.7 (recent)

70 (IDU ever)

30 (IDU ever)

100 (IDU ever)

100 (past 30 d)

8.9 (history of)

Male, % IDU, %

34

Mean
Age, y

Standard vaccine schedule

Control
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IVhetOR

Study
Asli, 2011
Bowman, 2014
Christensen, 2004
Hwang, 2010
Masson, 2013
Nyamathi, 2009
Nyamathi, 2015
Nyamathi, 2010
Seal, 2003
Topp, 2013
Weaver, 2014

% Weight
OR (95% CI)
19.00 (1.08–334.70)
0.4
1.92 (1.34–2.58)
33.6
6.86 (1.42–33.01)
1.5
1.58 (1.01–2.47)
18.0
34.44 (17.58–67.46)
8.0
1.85 (1.13–3.04)
14.7
1.20 (0.66–2.16)
10.3
1.00 (0.37–2.73)
3.6
10.30 (3.70–29.00)
3.4
3.30 (1.28–8.49)
4.0
13.95 (4.21–46.25)
2.5

0

8

16

24

32

100.0

40

OR
Figure 2. Forest plot of overall meta-analysis results using the Inverse Heterogeneity Model. Abbreviations: CI, confidence interval; IVhet OR, Inverse Heterogeneity Model
odds ratio; OR, odds ratio.

have decreased since 2003 and have not remained statistically
significant. Small-study bias was assessed using a funnel plot
(Supplementary Figure 3), plotting the natural log OR for each

study against its precision. Asymmetry in the funnel plot indicated potential small-study effects or other sources of bias such
as true heterogeneity between studies. Two subgroup analyses

IVhetOR by IVhetInterventionType

Study or subgroup

OR (95% CI)

% Weight

Schedule
Asli, 2011
Bowman, 2014

19.00 (1.08–334.70)

0.4

1.92 (1.34–2.58)

33.6

6.86 (1.42–33.01)

1.5

Hwang, 2010

1.58 (1.01–2.47)

18.0

Schedule subgroup

1.90 (1.14–3.14)

53.5

Seal, 2003

10.30 (3.70–29.00)

3.4

Topp, 2013

3.30 (1.28–8.49)

4.0

Weaver, 2014

13.95 (4.21–46.25)

2.5

Monetary subgroup

7.01 (2.88–17.06)

9.9

Christensen, 2004

Q = 5.69, P = .13, I 2 = 47%
Monetary

Q = 4.24, P = .12, I 2 = 53%
Case management/enhanced services
Masson, 2013

34.44 (17.58–67.46)

8.0

Nyamathi, 2009

1.85 (1.13–3.04)

14.7

Nyamathi, 2015

1.20 (0.66–2.16)

10.3

Nyamathi, 2010

1.00 (0.37–2.73)

3.6

2.92 (0.54–15.66)

36.6

2.53 (1.07–5.99)

100.0

Case management/enhanced services subgroup
Q = 68.07, P = .00, I 2 = 96%
Overall
Q = 94.53, P = .00, I 2 = 89%

0

8

16

OR

24

32

40

Figure 3. Forest plot of subgroup analysis by intervention type using the Inverse Heterogeneity Model. Abbreviations: IVhet OR, Inverse Heterogeneity Model odds ratio;
OR, odds ratio.
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2.53 (1.07–5.99)

Overall
Q = 94.53, P = .00,
I 2 = 89%

DISCUSSION

This systematic review and meta-analysis included 11 RCTs
or randomized studies that implemented strategies to increase
completion of the 3-dose HBV vaccine series in PWID. The
pooled OR for all 11 studies indicated a statistically significant

increase in the odds of completing all 3 doses in the intervention group compared with the control/comparison group (OR,
2.53; 95% CI, 1.07–5.99; P = .04). Subgroup analyses comparing
the interventions by type indicated that the odds of vaccine
completion in those who received financial incentives was the
highest, followed by receipt of an accelerated vaccine schedule.
Subgroup analysis of the case management/enhanced services
group yielded an OR that was not statistically significant. These
findings are consistent with WHO recommendations from
2014 that were based on previous research to increase compliance with HBV vaccination in PWID [3].
Hepatitis B is a vaccine-preventable disease that remains
problematic in certain at-risk groups. Since 2009, the increase
in IDU in the United States has highlighted the importance
of providing harm-reduction services to PWID, including access to HBV vaccine. However, making the vaccine available
does not always translate to increased HBV vaccination rates
in PWID. Strategies are needed to increase the vaccine uptake
among this at-risk group. The cost of the vaccine is minimal
compared with the savings from improved quality of life and
reduced health care costs. In 1 study, the cost of providing financial incentives to increase vaccine compliance was $220 per
participant compared with the cost of increasing compliance
through outreach methods, which equaled $590 per participant [7]. Combining financial incentives with an accelerated
vaccine schedule represents a low-cost and effective method for
increasing compliance.

IVhetOR by IVhetORtype

Study or subgroup
aOR
Bowman, 2014
Nyamathi, 2009
Nyamathi, 2010
Seal, 2003
Topp, 2013
Weaver, 2014
aOR subgroup

OR (95% CI)

% Weight

1.92 (1.34–2.58)

33.6

1.85 (1.13–3.04)

14.7

1.00 (0.37–2.73)

3.6

10.30 (3.70–29.00)
3.30 (1.28–8.49)
13.95 (4.21–46.25)

3.4
4.0
2.5

2.26 (1.02–4.97)

61.9

19.00 (1.08–334.70)

0.4

Q = 21.94, P = .00,
I 2 = 77%

OR
Asli, 2011
Christensen, 2004
Hwang, 2010
Masson, 2013
Nyamathi, 2015
OR subgroup

6.86 (1.42–33.01)

1.5

1.58 (1.01–2.47)

18.0

34.44 (17.58–67.46)

8.0

1.20 (0.66–2.16)

10.3

3.04 (0.49–18.88)

38.1

2.53 (1.07–5.99)

100.0

Q = 70.36, P = .00,
I 2 = 94%

Overall
Q = 94.53, P = .00,
I 2 = 89%

0

8

16

24

32

40

OR
Figure 4. Forest plot of subgroup analysis by type of reported odds ratio using the Inverse Heterogeneity Model. Abbreviations: aOR, adjusted odds ratio; IVhet OR, Inverse
Heterogeneity Model odds ratio; OR, odds ratio.
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comparing results by type of intervention and type of OR were
included in the analysis. Intervention types were categorized as
vaccine schedule, monetary/financial incentives, and case management/enhanced services (Figure 3). For the vaccine schedule
subgroup, the pooled OR was 1.90 (95% CI, 1.14–3.14), heterogeneity was not statistically significant (P = .13), and inconsistency was moderate (I2 = 47%). The pooled OR for the monetary
subgroup was 7.01 (95% CI, 2.88–17.06), heterogeneity was not
statistically significant (P = .12), and inconsistency was moderate (I2 = 53%). The case management/enhanced services subgroup pooled OR was not statistically significant (OR, 2.92;
95% CI, 0.54–15.66), heterogeneity was statistically significant
(P < .0001), and inconsistency was high (I2 = 96%). Finally, the
subgroup analysis of crude vs adjusted OR yielded the following
results: the pooled OR for studies that reported adjusted ORs
was 2.26 (95% CI, 1.02–4.97), heterogeneity was statistically
significant (P < .0001), and inconsistency was high (I2 = 77%);
the pooled OR for studies that reported crude ORs was 3.04
(95% CI, 0.49–18.88), heterogeneity was statistically significant
(P < .0001), and inconsistency was high (I2 = 94%) (Figure 4).

CONCLUSIONS

Increasing HBV vaccination is a cost-effective way of preventing
both primary and secondary infections in PWID. Using accelerated vaccine schedules and financial incentives has been shown
to increase compliance to the 3-dose vaccine schedule. As IDU

continues, more research is needed to find strategies to improve
health outcomes in this at-risk group.
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In 2017, the Food and Drug Administration approved
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strategies, for example, accelerated vaccine schedules with financial incentives, may confound the association and make it
difficult to determine the effectiveness of the individual intervention. Therefore, future studies should compare only 1 intervention strategy with 1 control group.
A potential limitation of this study was the significant amount
of heterogeneity between the 11 studies. However, this limitation was addressed through subgroup analysis of intervention
type, which indicated that heterogeneity was not significant
within 2 of the 3 subgroups. For this reason, the interpretation of the results from the intervention subgroup analysis may
be more appropriate than the pooled OR. Additionally, the 11
studies varied greatly on the percentage of people who reported
IDU. Ten of the 11 studies relied on self-reported drug use and
may have been influenced by bias. There was substantial variation in how and when people were randomized to the intervention and control groups. All of the studies took place in either
prison or urban areas, which may affect generalizability, especially to PWID living in rural areas. Generalizability to females
may also be problematic due to the majority of participants
being males. Some of the studies were part of larger studies,
and data for the vaccine-eligible population were not always reported. Publication bias and small-study effects may have influenced the overall findings of the study, resulting in statistically
significant results. Finally, coding studies proved problematic
due to the quality of reporting. Several of the studies reported
conflicting information in the text, charts, and tables, making it
difficult to determine the true numbers.
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